Nurix Therapeutics Inc (NASDAQ:NRIX) saw its stock jump 10% on Wednesday after announcing the start of its pivotal DAYBreak ...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment ...

Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) stock surged 10% on Wednesday after the company announced the initiation of its pivotal DAYBreak clinical trial, a single-arm Phase 2 study of ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a Phase 2 clinical study ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

The global chronic lymphocytic leukemia therapeutics market is poised for steady expansion, with an expected compound annual growth rate (CAGR) of 7% from 2025 to 2030. Growth is driven by rapid ...